Our results indicate that intranasal delivery of Fasudil-modified MNCs have therapeutic potential in EAE, providing a safe and effective cell therapeutic strategy to MS and/or other related disorders.
| INTRODUC TI ON
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), which leads to neurological impairment and most often affects young adults, with heavy burdens for the family and society. So far, no clinically effective therapy has been established to prevent neuronal damage in MS. The drugs approved by Food and Drug Administration (FDA) for the treatment of MS, such as interferon-β, glatiramer acetate and Fingolimod, can alleviate the symptoms to a certain extent and reduce relapse frequency, whereas they are not effective for all patients of MS and do not influence the irreversible dysfunction and disease progres-
sion.
1,2 It is particularly urgent to find and study effective treatment strategies for MS patients with small side effect and low cost. producing Th17 cells are the main participators in the development of EAE, which is closely related to neuroinflammation and myelin loss. 6, 7 Th2 T cells act as immunomodulatory cells and possess the effect of antiinflammatory and myelin protection, which can improve the severity of EAE. 8 Macrophages, an important antigen presenting cells of immune system, participate in the induction and regulation of inflammatory microenvironment. Classically activated macrophages (M1) can activate Th1 and Th17 of T cells and enlarge immunological response.
Experimental autoimmune encephalomyelitis (EAE)
Alternative activated macrophages (M2) can take part in mediating the differentiation of Th2 cells and CD4 + CD25 + regulatory T cells, which contributes to the myelin regeneration and neuronal survival. [9] [10] [11] Rho-kinase (ROCK), is expressed both centrally and peripherally where it is involved in fundamental cellular processes, including differentiation, migration, proliferation and survival. 12, 13 A series of studies have discovered that many neurodegenerative diseases, such as MS, Alzheimer's disease and Parkinson's disease, have the activation of ROCK signaling pathway that affects the occurrence and development of these diseases. [14] [15] [16] Although Fasudil shows good therapeutic effects in EAE, the following factors restrict its clinical application in MS patients: (a) rapid and obvious vasodilatation; (b) poor oral bioavailability and no oral drug; (c) smaller safety window for long-term use. 19 In recent years, cellular immunotherapy has become a hot spot in the field of neurological disorders and has made great progress, which has the advantages including autologous transplantation, economic security, no ethical problems and tumorigenicity. 20, 21 Intranasal administration is a safe and effective delivery in the treatment of CNS diseases.
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Previous studies show that Fasudil also influence the polarization of T cells and macrophages. 23 In this study, we try to explore the thera- Cells were then washed three times and re-suspended in medium.
| MATERIAL S AND ME THODS

| Animals
| Preparation of encephalitogenic MNCs in vivo
Cells were adjusted to 3×10 6 /mL. Subsequently, encephalitogenic
MNCs were treated with Fasudil (15 μg/mL) or phosphate buffered solution (PBS) in the presence of IL-2 (20 ng/mL) and MOG (10 μg/mL) for 72 hour at 37°C with 5% CO 2 .
| Induction of EAE and intranasal administration of MNCs
Mice were divided into two groups: Fasudil-MNCs (n = 10) and PBSMNCs (n = 10 
| Histology and immunohistochemistry
On day 28 p.i., mice were perfused with NS and 4% buffered par- For immunohistochemistry, sections were blocked with 1% albumin from bovine serum (BSA) (Serotec, Bicester, UK) for 30 minutes and incubated with anti-CD4 (1:1000; clone A60; Sigma), anti-CD68
(1:1000; Serotec) and anti-microtubule associated protein 2 (MAP2)
(1:200; Millipore, Bedford, MA, USA) at 4°C overnight, followed by the corresponding secondary antibodies at room temperature (RT) for 2 hour. As a negative control, additional sections were treated similarly, but the primary antibodies were omitted. The expressions of CD4 + T cells, CD68 + macrophages and MAP2 were determined by Image-Pro Plus software.
| Flow cytometry analysis
On day 28 p.i., mice were sacrificed and spleens were removed under aseptic conditions. MNCs were prepared as above described stained (CCR7) (eBioscience). At least 10 000 events were collected using flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and data were analysed using CellQuest software (BD Biosciences).
| Western blot analysis
On day 28 p.i., mice were perfused with NS and spinal cords were homogenized with a microcontent motoroperated tissue homogenizer (Kimble Kontes, Vineland, NJ, USA), using protein extraction kit (Millipore) supplemented with a cocktail of protease inhibitors.
The homogenates were centrifuged at 20 000 g for 20 minutes at 4°C, and the supernatants were collected. Protein extract (20 μg)
were separated by SDS-PAGE and electroblotted onto nitrocellulose membrane (Immobilon-P; Millipore). After blocking with 5% nonfat dry milk, the membranes were incubated at 4°C overnight with the following antibodies: antiinducible nitric oxide synthase 
| Cytokines by enzyme linked immunosorbent assay
On day 28 p.i., mice were sacrificed and spleens were removed under aseptic conditions. Splenic MNCs (6 × 10 5 /mL) were cultured for 48 hour at 37°C in the presence of MOG (10 μg/mL).
Supernatants were collected and measured for cytokine concentrations of IL-17, IL-10 (eBioscience Inc), IL-6, tumor necrosis factor (TNF-α) (PeproTech Inc., Hawthorne, NJ, USA) and IL-1β (Invitrogen Inc., Carlsbad, CA, USA) using sandwich enzyme linked immunosorbent assay (ELISA) kits in accordance with the manufacturer's instructions. The quantitation of cytokines was calculated by reference to standard curves. Determinations were performed in triplicate and results were expressed as pg/mL.
| Statistical analysis
GraphPad Prism software (Cabit Information Technology Co., Ltd., Shanghai, China) was used for statistical analysis. The data of clinical mean score was analysed with the Mann-Whitney U test; other data were analysed with Student's t test. A statistically significant difference was assumed at P < 0.05.
| RE SULTS
| Fasudil-modified MNCs ameliorates severity of EAE via nasal delivery
In the present study, mice were immunized with MOG peptide to induce EAE model. As shown in Table 1 and Figure 1 , the incidence in 
| Fasudil-modified MNCs inhibits inflammation and improves demyelination in spinal cords
In the spinal cord of EAE, the inflammatory infiltration CNS and demyelination are major pathological manifestation. As shown in Figure 2A ,B, nasal delivery of Fasudil-modified MNCs obviously reduced inflammatory infiltration (P < 0.001) and improved demyelina- Figure 2C , all P < 0.01).
| Fasudil-modified MNCs regulate peripheral T cells and macrophages
The activation of the peripheral immune system is the initiating factor in the pathogenesis of EAE, which can infiltrate to CNS and lead to immune attacks and meylin damage. To detect the effect of (P < 0.001), IL-12 (P < 0.01) and CD8a (P < 0.05) and increased the subsets of CD11b + macrophages expressing M2 markers CD206 (P < 0.01), CD200 (P < 0.001) and CD14 (P < 0.001), as compared with PBS-treated MNCs control.
Based on literature review, iNOS, COX-2 and Arg-1 are three representatives of M1 and M2 macrophages. We further measured the expression of iNOS, COX-2 and Arg-1 in spinal cords by western blot.
As shown in Figure 5 , nasal delivery of Fasudil-modified MNCs significantly suppressed expression of COX-2 (P < 0.01) and increased expression of Arg-1 (P < 0.001). There was no significant difference on the expression of iNOS between Fasudil-MNCs group and PBSMNCs group in spinal cord.
| Fasudil-modified MNCs inhibit inflammatory responses in EAE
Neuroinflammation played an important role in the pathogenesis of EAE, involving the release of inflammatory cytokines and the activa- 
| Fasudil-modified MNCs induce the expression of neurotrophic factors in spinal cord
It is speculated that the improvement of inflammatory microenvironment can reduce neuron damage. As shown in Figure 
| D ISCUSS I ON
Our previous studies found that Fasudil, when injected intraperitoneally in early and late stages of EAE induction, ameliorated the clinical severity of EAE, improved demyelination and inhibited the infiltration of inflammatory cells. 
25
Cells can enter straight through the olfactory nerve and olfactory tract into the cranial cavity and connect with mitral cell and plexus cells in the olfactory bulb by synapsis, which form the olfactory mucosa epithelium pathway. 26, 27 This route minimizes the distribution and first pass effect of immune cells in peripheral organs and allows rapid drug delivery directly from nasal mucosa to the brain. There are currently more than 300 clinical trials under way in the USA alone using intranasal administration. [28] [29] [30] Our previous study showed that the treatment effect of nasal administration was superior to that of intraperitoneal injection in PD model mice and nasal delivery of the Fasudil derivative inhibited the development of EAE. 22, 29 In the present research, nasal delivery of Fasudil-modified MNCs exhibited therapeutic potential by regulating the peripheral immune responses and inhibiting the central inflammatory microenvironment, which provide a safe and effective option for the treatment of MS.
The activation of macrophage/microglia is considered to be an important factor in causing demyelination and neurodegeneration. 17, 18 Axonal damage may be positively correlated with the activation of inflammatory macrophage/microglia. 31, 32 Macrophage is usually classified into Ml and M2 phenotype based on different Results are shown as mean ± SEM of five mice in each group. Differences are analyzed using Student's t-test. **P < 0.01; ***P < 0.001 In spinal cords, Fasudil-modified MNCs suppressed the expression of P38. Furthermore, Fasudil-modified MNCs decreased the production of inflammatory cytokines IL-17, TNF-α, IL-6 and increased antiinflammatory IL-10 production in culture supernatant of splenocytes. 51 Our data suggested that inhibiting the activation of NF-κB-p38 signaling pathway was a possible target of Fasudilmodified MNCs in the treatment of EAE. In addition, NF-κB is a key transcription factor that is related to the activation of M1 macrophage, while P38 could mediate inflammatory injury under microglia activation. 52, 53 Moreover, inflammation and oxidative stress also enhanced the expressions of NF-κB and P38, which eventually formed a vicious circle. 
| CON CLUS ION
In conclusion, our findings provide evidence that nasal delivery of Fasudil-modified MNCs delays the onset and ameliorates the severity in EAE mice, accompanied by the improvement of demyelination. 
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